Back to Publications
August, 2021
MORNINGSKY Trial
BlueClinical is involved, through its Clinical Research Partnership Network, on the Phase 3 MORNINGSKY trial
BlueClinical is involved, through its Clinical Research Partnership Network, on the Phase 3 MORNINGSKY trial, a global multicenter study evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting.
Learn more at https://www.covid19morningsky.com/PT
Other Publication
BlueClinical @ Swiss Biotech Day 2023
BlueClinical will be present at Swiss Biotech Day 2023. It will be held on April 24-25, 2023 in Basel, Switzerland. Contact us to schedule a meeting at: bd@blueclinical.pt
BlueClinical is a proud gold sponsor of the 2nd Bioequivalence Workshop
We are happy to announce that BlueClinical is a proud gold sponsor of the 2nd Bioequivalence Workshop by Medicines for Europe, which is scheduled to take place on 26 April 2023 in Brussels, Belgium.
